Nautilus Biotechnology, Inc. (NAUT) stock
NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
$2.12−0.05 (-2.30%)
Close on Nov 20, 2026Market cap $270.03MP/E –Yield –
Nautilus Biotechnology free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Nautilus Biotechnology's free cash flow for the twelve months ending Sep 30, 2026 was -$55.14M. For fiscal 2025 it was -$51.97M. The highest annual figure on record is -$14.92M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$51.97M | – |
| FY2024 | Dec 31, 2024 | -$61.27M | – |
| FY2023 | Dec 31, 2023 | -$54.15M | – |
| FY2022 | Dec 31, 2022 | -$48.13M | – |
| FY2021 | Dec 31, 2021 | -$41.51M | – |
| FY2020 | Dec 31, 2020 | -$14.92M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$14.73M | – |
| Q2 FY2026 | Jun 30, 2026 | -$14.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.61M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.62M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.45M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.82M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.22M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.82M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.51M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.45M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.74M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.03M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.63M | – |
See a number that looks wrong?